Pancreatic Cancer Research

ResearcherAbramson Cancer CenterActive in the last 2 years

John Peter Plastaras

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4916-9857; OpenAlex author ID A5090230371. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2011: 1 paper, 1 trial · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Co-author DOI 10.1002/cncr.35936↗
  2. SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.35058↗
  3. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  4. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000854↗
  5. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
  6. Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. Last author DOI 10.21037/jgo.2017.03.04↗
  7. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally a… Co-author DOI 10.1007/s00280-013-2147-4↗
  8. Feasibility of electromagnetic transponder use to monitor inter- and intrafractional motion in locally advanced pancreatic cancer patients. Co-author DOI 10.1016/j.ijrobp.2011.07.025↗
  9. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. Last author DOI 10.6092/1590-8577/449↗

Trials 1

  1. Proton Radiotherapy for Upper Gastrointestinal Malignancies Principal investigator NCT01449864↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. James M. Metz · 7 shared papers, 2012–2025 · strength 0.68
  2. Edgar Ben‐Josef · 5 shared papers, 2017–2025 · strength 0.61
  3. Mark H. O’Hara · 3 shared papers, 2018–2025 · strength 0.37
  4. Charles M. Vollmer · 2 shared papers, 2018–2025 · strength 0.27
  5. Thomas Benjamin Karasic · 1 shared paper, 2025 · strength 0.21
  6. Andre A. Konski · 1 shared paper, 2025 · strength 0.21
  7. Uri Amit · 1 shared paper, 2025 · strength 0.21
  8. Erica L. Carpenter · 1 shared paper, 2025 · strength 0.21
  9. Kim A. Reiss-Binder · 1 shared paper, 2025 · strength 0.21
  10. Jeffrey A. Drebin · 3 shared papers, 2013–2021 · strength 0.20
  11. Emily J. Anstadt · 1 shared paper, 2024 · strength 0.18
  12. Nikhil Yegya‐Raman · 1 shared paper, 2024 · strength 0.18
  13. Jacob Ezra Shabason · 2 shared papers, 2018–2021 · strength 0.17
  14. Kim A. Reiss · 2 shared papers, 2018–2021 · strength 0.17
  15. Theodore Sunki Hong · 1 shared paper, 2021 · strength 0.11
  16. William F. Regine · 1 shared paper, 2021 · strength 0.11
  17. John Parker Hoffman · 1 shared paper, 2021 · strength 0.11
  18. Adham Sean Bear · 1 shared paper, 2021 · strength 0.11
  19. Ross Allen Abrams · 1 shared paper, 2021 · strength 0.11
  20. William Tristram Arscott · 1 shared paper, 2021 · strength 0.11
  21. Danielle S. Bitterman · 1 shared paper, 2021 · strength 0.11
  22. Howard P. Safran · 1 shared paper, 2021 · strength 0.11
  23. Christopher H. Crane · 1 shared paper, 2021 · strength 0.11
  24. Charles S. Fuchs · 1 shared paper, 2021 · strength 0.11
  25. Al B. Benson · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.